Coherus Biosciences Inc
General ticker "CHRS" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $173.4M
Coherus Biosciences Inc does not follow the US Stock Market performance with the rate: -28.7%.
Estimated limits based on current volatility of 4.3%: low 1.42$, high 1.55$
Factors to consider:
- Current price 21.3% below estimated low
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [1.82$, 4.76$]
- 2024-12-30 to 2025-12-30 estimated range: [2.36$, 5.71$]
Financial Metrics affecting the CHRS estimates:
- Negative: Non-GAAP EPS, $ of -2.02 <= 0.10
- Negative: Operating profit margin, % of -44.13 <= 1.03
- Negative: Operating cash flow per share per price, % of -46.25 <= 2.35
- Negative: Industry operating cash flow per share per price (median), % of -23.87 <= 3.85
- Negative: negative Net income
- Positive: Interest expense per share, $ of 0.43 <= 0.74
Short-term CHRS quotes
Long-term CHRS plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $326.55MM | $211.04MM | $257.24MM |
| Operating Expenses | $590.41MM | $467.92MM | $460.44MM |
| Operating Income | $-263.86MM | $-256.88MM | $-203.20MM |
| Non-Operating Income | $-23.24MM | $-34.87MM | $-35.07MM |
| Interest Expense | $22.96MM | $32.47MM | $40.54MM |
| R&D Expense | $363.11MM | $199.36MM | $109.44MM |
| Income(Loss) | $-287.10MM | $-291.75MM | $-238.27MM |
| Taxes | $0.00MM | $0.00MM | $-0.38MM |
| Profit(Loss) | $-287.10MM | $-291.75MM | $-237.89MM |
| Stockholders Equity | $97.73MM | $-137.42MM | $-193.43MM |
| Inventory | $93.25MM | $115.05MM | $62.60MM |
| Assets | $679.33MM | $480.85MM | $629.60MM |
| Operating Cash Flow | $-37.43MM | $-241.12MM | $-174.88MM |
| Capital expenditure | $1.29MM | $2.04MM | $0.29MM |
| Investing Cash Flow | $-138.41MM | $-166.85MM | $144.64MM |
| Financing Cash Flow | $51.88MM | $54.33MM | $69.60MM |
| Earnings Per Share* | $-4.06 | $-4.21 | $-2.53 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.